{"id":"W2955839328","doi":"10.1002/cncr.32190","title":"Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb; Ono Pharmaceutical; National Institute for Health and Care Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Nivolumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Randomized controlled trial; Clinical trial; Head and neck squamous-cell carcinoma; Target lesion; Immunotherapy; Phases of clinical research; Head and neck cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001017868,0.0001731842,0.001669967,0.000251928,0.0000153803,0.00000600054,0.00007783881,0.00007732548,0.000271833],"category_scores_gemma":[0.0001295491,0.00009075987,0.0005176524,0.0008877549,0.0001860919,0.00003073852,0.00002437215,0.0001186116,4.281528e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002443331,"about_ca_system_score_gemma":0.0003885764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001978994,"about_ca_topic_score_gemma":0.002764683,"domain_scores_codex":[0.9977272,0.0003946114,0.001154009,0.0003073169,0.0002329657,0.000183872],"domain_scores_gemma":[0.9986143,0.0004104111,0.0005127826,0.0003537934,0.0000556278,0.00005312487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8960943,0.002222993,0.04386863,0.0001821468,0.0005498742,0.00001011142,0.0009527866,0.00000555127,0.001899116,0.000002455425,0.0000309458,0.05418114],"study_design_scores_gemma":[0.9548611,0.004957402,0.03167572,0.0003281887,0.002276144,0.000001744402,0.0001267487,0.00212272,0.003269661,0.000007467405,0.0002586178,0.000114467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883615,0.007814641,0.000002270986,0.0002022006,0.0003306485,0.003106599,0.0000566765,0.00000425235,0.0001211548],"genre_scores_gemma":[0.9979928,0.001093425,0.000113314,0.00005436952,0.00002841803,0.00031365,0.00002144657,0.00001262697,0.0003699329],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05876686,"threshold_uncertainty_score":0.370108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05610088972359639,"score_gpt":0.403699092824067,"score_spread":0.3475982031004706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}